Sac-TMT with Avastin for EGFR-mutant lung cancer with brain metastases
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs (Sac-TMT and bevacizumab) for people with a specific type of non-small cell lung cancer that has spread to the brain and has stopped responding to a certain targeted therapy. The goal is to see if this combination can shrink brain tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have non-squamous non-small cell lung cancer with an EGFR mutation (exon 19 deletion or L858R).
- Your cancer must have worsened while on or after a third-generation EGFR-targeted pill (like osimertinib).
- You must have at least one brain metastasis that is at least 5 mm and has not been treated with radiation or surgery.
- You must be in good general health (ECOG 0-1) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, Sac-TMT and bevacizumab, as a second treatment option for people with advanced non-squamous non-small cell lung cancer whose cancer has gotten worse after initial chemotherapy and immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This study tests a new drug called sacituzumab tirumotecan (Sac-TMT) combined with radiation to the brain for people with EGFR-mutant lung cancer that has spread to the brain and has grown despite first-line EGFR inhibitor therapy. The goal is to see if this combination can control the brain tumors better.
This trial tests a new drug (Sacituzumab Tirumotecan) combined with a third-generation EGFR pill, with or without radiation, for people with EGFR-mutant lung cancer that has spread to the brain and has stopped responding to prior targeted therapy.
This trial tests a combination of two drugs (Sac-TMT and bevacizumab) to treat triple-negative breast cancer that has spread to the brain. Triple-negative means the cancer cells lack three common markers, making it harder to treat with standard therapies.
This trial tests a new drug called sacituzumab tirumotecan (Sac-TMT) for people with triple-negative breast cancer that has spread to the brain. It aims to see if the drug can shrink or control brain tumors without needing immediate radiation or surgery.
This trial is testing a new drug called Sac-TMT for people with advanced ovarian cancer that has not responded well to initial platinum-based chemotherapy and does not have a specific gene change called HRD. It aims to see if this drug can work better than standard treatment.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.